

Susan H.

94644

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Howard Owens Examiner #: 74908 Date: 5-15-03
 Art Unit: 1623 Phone Number 306-4538 Serial Number: 09/925,673
 Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): PAPER DISK E-MAIL
839 CM1/8317

If more than one search is submitted, please prioritize searches in order of need.

 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Point of Contact
 Susan Hanley
 Technical Info. Specialist
 CM1 6805 Tel: 305-4053

Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search claims 1-3, 9, 10-18, 55,
 62 + 63.

Susan,

I know that this structure appears to be broad because of the number of substituents; however, according to the summary of the invention, the novelty appears to be the ether bond (2'-4' link) present in the sugar portion. If the ether bond configuration can be found, most likely the other substituents will be secondary since they are only included to account for various oligonucleotide links and supports.

Thanks,
 Howard

STAFF USE ONLY

Searcher: Hanley

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: 5/18Date Completed: 5/22Searcher Prep & Review Time: 25

Clerical Prep Time: _____

Online Time: 15

Type of Search

NA Sequence (#) _____

AA Sequence (#) _____

Structure (#) 1

Bibliographic _____

Litigation _____

Fulltext _____

Patent Family _____

Other _____

Vendors and cost where applicable

(STN)

5 2 2 0

Dialog _____

Questel/Orbit _____

Dr.Link _____

Lexis/Nexis _____

Sequence Systems _____

WWW/Internet _____

Other (specify) _____


Best Available Copy

=> d. que

L12

STR

Hy 16 ← nitrogenous base, at least 2N, 4C



REP G1=(1-4) C

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 16

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS M4 C M2 N AT 16

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L14

255 SEA FILE=REGISTRY SSS FUL L12

225 opds

L15

6 SEA FILE=CAPLUS ABB=ON PLU=ON L14

6 citations

=> d ibib abs hitstr 1-6

L15 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2003:320053 CAPLUS
 TITLE: Modified antisense oligonucleotides for
 down-regulation of VEGF mRNA expression
 INVENTOR(S): Koizumi, Makoto; Morita, Koji
 PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
 SOURCE: PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003033696	A1	20030424	WO 2002-JP10796	20021017
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: JP 2001-320096 A 20011018
 AB A compd. represented by the general formula HO-B1-B2-B3-B4-B5-B6-B7-B8-B9-B10-B11-B12-B13-B14-B15-B16-B17-B18-B19-B20-B21-B22-H wherein B1 to B3, B8, B11, and B20 are the same or different and each represents Cp, Cs, or Ce (p = 2'-deoxyribo-; s = 3'-phosphorothioate; e = 2'-O,4'-C-C1-5-alkylene-bridged).; B4, B5, B7, B9, B12, B14 to B16, and B21 are the same or different and each represents Ap, As, or Ae; B6, B10, B13, and B17 are the same or different and each represents Gp, Gs, or Ge; B18 and B19 are the same or different and each represents Tp, Ts, or Te; and B22 represents T or Te, having activity for inhibiting vascular endothelial growth factor (VEGF) expression; and a pharmacol. acceptable salt of the compd.; are disclosed. The authors studied the properties of 2'-O,4'-C-ethylene-bridged nucleic acid (ENA) oligonucleotides as antisense mols. Compared to a phosphorothioate (PS) DNA and RNA heteroduplex, a duplex of an ENA/PS/ENA gapmer with RNA was a more effective substrate for RNase H-mediated cleavage. They designed ENA antisense oligonucleotides (AON) targeting human VEGF mRNA. ENA AON with a cationic polymer considerably down-regulated VEGF mRNA expression, while no down-regulation by PS AON was obsd. They also investigated the influence on the gene expression of genes other than VEGF by a gene database homol. search and RT-PCR anal. This method turned out to be an efficient approach to search for non-target genes sequence-specifically down-regulated by AON. In rat plasma, an ENA/PS/ENA gapmer was very stable after 24 h, while a bridged nucleic acid (BNA) or locked nucleic acid (LNA) oligonucleotide and a PS oligonucleotide were half degraded in 4 h. The high stability of ENA oligonucleotides in plasma would make ENA oligonucleotides ideal for in vivo studies.


IT INDEXING IN PROGRESS
 IT 287737-36-4 287737-40-0 287737-45-5
 287737-58-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(modified antisense oligonucleotides for down-regulation of VEGF mRNA expression)

RN 287737-36-4 CAPLUS

CN Benzamide, N-[1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-40-0 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-45-5 CAPLUS


CN Benzamide, N-[9-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-9H-purin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287737-58-0 CAPLUS
 CN Propanamide, N-[9-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-
 .alpha.-L-lyxo-hexofuranosyl]-6,9-dihydro-6-oxo-1H-purin-2-yl]-2-methyl-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:974510 CAPLUS
 DOCUMENT NUMBER: 138:181616
 TITLE: Effects on RNA interference in gene expression (RNAi)
 in cultured mammalian cells of mismatches and the

introduction of chemical modifications at the 3'-ends of siRNAs

AUTHOR(S): Hamada, Makiko; Ohtsuka, Toshiaki; Kawaida, Reimi; Koizumi, Makoto; Morita, Koji; Furukawa, Hidehiko; Imanishi, Takeshi; Miyagishi, Makoto; Taira, Kazunari

CORPORATE SOURCE: Biomedical Research Laboratories, Sankyo Co., Ltd., Tokyo, 140-8710, Japan

SOURCE: Antisense & Nucleic Acid Drug Development (2002), 12(5), 301-309
CODEN: ANADF5; ISSN: 1087-2906

PUBLISHER: Mary Ann Liebert, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The highly specific posttranscriptional silencing of gene expression induced by double-stranded RNA (dsRNA) is known as RNA interference (RNAi) and has been demonstrated in plants, nematodes, *Drosophila*, and protozoa, as well as in mammalian cells. The suppression of expression of specific genes by chem. synthesized 21-nucleotide (21-nt) RNA duplexes has been achieved in various lines of mammalian cells, and this technique might prove to be a valuable tool in efforts to analyze biol. functions of genes in mammalian cells. In order to investigate the utility of potential modifications that can be introduced into small interfering RNAs (siRNAs) and also to study their functional anatomy, we synthesized different types of siRNA targeted to mRNA of Jun dimerization protein 2 (JDP2). Our detailed anal. demonstrated that siRNAs with only one mismatch, relative to the target, on the antisense strand had reduced RNAi effect, whereas the corresponding mutation on the sense strand did not interfere with the RNAi. Moreover, one 2-hydroxyethylphosphate (hp) substitution at the 3'-end of the antisense strand but not of the sense strand also prevented RNAi, whereas a related modification at the 3'-end of either strand, using 2'-O,4'-C-ethylene thymidine (eT), which is a component of ethylene-bridge nucleic acids (ENA), completely abolished RNAi. These results support the hypothesis that the two strands have different functions in RNAi in cultured mammalian cells and indicate that their chem. modification of siRNAs at the 3'-end of the sense strand exclusively is possible, without loss of RNAi activity, depending on the type of modification. Because modification at the 3'-end of the antisense strand by hp or eT abolished the RNAi effect, it appears possible that the 3'-end is recognized by the RNA-induced silencing complex (RISC).

IT 287737-40-0


RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(3' end of siRNA modified by, abolishing RNA interference; modifications of siRNA affect RNA interference of JDP2 protein gene expression in mammalian cells)

RN 287737-40-0 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-5-methyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:847786 CAPLUS
 DOCUMENT NUMBER: 137:338099
 TITLE: 2'-O,4'-C-ethylene-bridged nucleoside triphosphates
 RNA polymerase substrates and influenza drug
 INVENTOR(S): Koizumi, Makoto; Morita, Hiroshi; Kaneko, Masakatsu;
 Imanishi, Takeshi
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 30 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002322192	A2	20021108	JP 2001-241032	20010808
PRIORITY APPLN. INFO.:			JP 2000-242233	A 20000810
OTHER SOURCE(S):	MARPAT 137:338099			

GI



AB 2'-O,4'-C-ethylene-bridged nucleoside triphosphates represented by general

formula [I; A = C1-4 alkylene; B = purin-9-yl, 2-oxo-1,2-dihydropyrimidin-1-yl optionally substituted with halogen, mercapto, amino, C1-4-alkyl, C1-4-alkoxy, C1-4-alkylthio, C1-4-alkyl substituted amino; X = O, S], useful as substrates for RNA polymerase-catalyzed amplification method, are disclosed. Utility of those compds. as substrates for RNA polymerase-catalyzed amplification method, and inhibitors of influenza virus polymerase, was demonstrated.

IT 474323-29-0P 474323-30-3P 474323-31-4P
 474323-32-5P 474323-33-6P 474323-34-7P
 474323-35-8P 474323-36-9P 474323-37-0P
 474323-38-1P 474323-39-2P 474323-40-5P
 474323-41-6P 474323-42-7P 474323-43-8P
 474323-44-9P 474323-45-0P 474323-46-1P
 474323-47-2P 474323-48-3P 474323-49-4P
 474323-50-7P 474323-51-8P 474323-52-9P
 474323-53-0P 474323-54-1P 474323-55-2P
 474323-56-3P 474323-57-4P 474323-58-5P
 474323-59-6P 474323-60-9P 474323-61-0P
 474323-62-1P 474323-63-2P 474323-64-3P
 474323-65-4P 474323-67-6P 474323-69-8P
 474323-72-3P 474323-75-6P 474323-77-8P
 474323-79-0P 474323-81-4P 474323-83-6P
 474323-85-8P 474323-86-9P 474323-87-0P
 474323-88-1P 474323-89-2P 474323-90-5P
 474323-91-6P 474323-92-7P 474323-93-8P
 474323-94-9P 474323-95-0P 474323-96-1P
 474323-97-2P 474323-98-3P 474323-99-4P
 474324-01-1P 474324-02-2P 474324-03-3P
 474324-04-4P 474324-05-5P 474324-06-6P
 474324-08-8P 474324-09-9P 474324-10-2P
 474324-11-3P 474324-12-4P 474324-13-5P
 474324-14-6P 474324-15-7P 474324-16-8P
 474324-17-9P 474324-18-0P 474324-19-1P
 474324-20-4P 474324-21-5P 474324-22-6P
 474324-23-7P 474324-24-8P 474324-25-9P
 474324-26-0P 474324-27-1P 474324-28-2P
 474324-29-3P 474324-30-6P 474324-31-7P
 474324-32-8P 474324-33-9P 474324-34-0P
 474324-35-1P 474324-36-2P 474324-37-3P
 474324-38-4P 474324-39-5P 474324-41-9P
 474324-42-0P 474324-43-1P 474324-44-2P
 474324-45-3P 474324-46-4P 474324-47-5P
 474324-48-6P 474324-49-7P 474324-51-1P
 474324-52-2P 474324-53-3P 474324-54-4P
 474324-55-5P 474324-57-7P 474324-58-8P
 474324-59-9P 474324-60-2P 474324-62-4P
 474324-63-5P 474324-64-6P 474324-65-7P
 474324-66-8P 474324-67-9P 474324-68-0P
 474324-69-1P 474324-71-5P 474324-72-6P
 474324-73-7P 474324-74-8P 474324-75-9P
 474324-76-0P 474324-78-2P 474324-79-3P
 474324-80-6P 474324-81-7P 474324-82-8P
 474324-84-0P 474324-85-1P 474324-86-2P
 474324-87-3P 474324-88-4P 474324-89-5P
 474324-90-8P 474324-91-9P 474324-92-0P
 474324-94-2P 474324-95-3P 474324-96-4P
 474324-97-5P 474324-98-6P 474325-00-3P
 474325-01-4P 474325-02-5P 474325-03-6P
 474325-04-7P 474325-06-9P 474325-07-0P
 474325-08-1P 474325-09-2P 474325-10-5P


474325-11-6P 474325-12-7P 474325-13-8P
 474325-15-0P 474325-16-1P 474325-17-2P
 474325-18-3P 474325-19-4P 474325-21-8P
 474325-22-9P 474325-23-0P 474325-24-1P
 474325-25-2P 474325-27-4P 474325-28-5P
 474325-29-6P 474325-30-9P 474325-31-0P
 474325-32-1P 474325-34-3P 474325-35-4P
 474325-36-5P 474325-37-6P 474325-38-7P
 474325-39-8P 474325-40-1P 474325-41-2P
 474325-42-3P 474325-43-4P 474325-44-5P
 474325-45-6P 474325-46-7P 474325-47-8P
 474325-48-9P 474325-49-0P 474325-50-3P
 474325-51-4P 474325-52-5P 474325-53-6P
 474325-54-7P 474325-55-8P 474325-56-9P
 474325-57-0P 474325-58-1P 474325-59-2P
 474325-60-5P 474325-61-6P 474325-62-7P
 474325-63-8P 474325-64-9P 474325-65-0P
 474325-66-1P 474325-67-2P 474325-68-3P
 474325-69-4P 474325-70-7P 474325-71-8P
 474325-72-9P 474325-73-0P 474325-74-1P
 474325-75-2P 474325-76-3P 474325-77-4P
 474325-78-5P 474325-99-0P

RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(2'-O,4'-C-ethylene-bridged nucleoside triphosphates RNA polymerase substrates and influenza drug)


RN 474323-29-0 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-11-hydroxy-10-(9H-purin-9-yl)-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-30-3 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-10-(2-amino-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-31-4 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-10-(1,2-dihydro-2-oxo-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-32-5 CAPLUS

CN Triphosphoric acid, P-[(1R,8R,10R,11S)-10-(1,6-dihydro-6-oxo-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-33-6 CAPLUS

CN Triphosphoric acid, P-[(1R,8R,10R,11S)-10-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-34-7 CAPLUS

CN Triphosphoric acid, P-[(1R,8R,10R,11S)-11-hydroxy-10-(1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-9-yl)-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-35-8 CAPLUS

CN Triphosphoric acid, P-[(1R,8R,10R,11S)-10-(6-amino-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-36-9 CAPLUS

CN Triphosphoric acid, P-[(1R,8R,10R,11S)-10-(2,6-diamino-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-37-0 CAPLUS

CN Triphosphoric acid, P-[(1R,8R,10R,11S)-10-(6-amino-2-chloro-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-38-1 CAPLUS

CN Triphosphoric acid, P-[(1R,8R,10R,11S)-10-(6-amino-2-fluoro-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-39-2 CAPLUS

CN Triphosphoric acid, P-[(1R,8R,10R,11S)-10-(6-amino-2-bromo-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-40-5 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-10-(6-amino-1,2-dihydro-2-oxo-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-41-6 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-11-hydroxy-10-(6-methoxy-9H-purin-9-yl)-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-42-7 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-10-(2,6-dimethoxy-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-43-8 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-10-(2-amino-6-methoxy-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-44-9 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-10-(6-chloro-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-45-0 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-10-(6-bromo-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-46-1 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-10-(6-fluoro-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474323-47-2 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-10-(2,6-dichloro-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)



RN 474323-48-3 CAPLUS


CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-10-(1,6-dihydro-6-thioxo-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI)
(CA INDEX NAME)



RN 474323-49-4 CAPLUS

CN 9H-Purine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-50-7 CAPLUS

CN 9H-Purin-2-amine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-51-8 CAPLUS

CN 2H-Purin-2-one, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-52-9 CAPLUS

CN 6H-Purin-6-one, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-53-0 CAPLUS

CN 6H-Purin-6-one, 2-amino-9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-54-1 CAPLUS

CN 1H-Purine-2,6-dione, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-3,9-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-55-2 CAPLUS

CN 9H-Purin-6-amine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)]-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-56-3 CAPLUS

CN 9H-Purine-2,6-diamine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)]-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-57-4 CAPLUS

CN 9H-Purin-6-amine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)]-alpha.-L-lyxohexofuranosyl]-2-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-58-5 CAPLUS

CN 9H-Purin-6-amine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)]-alpha.-L-lyxohexofuranosyl]-2-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-59-6 CAPLUS

CN 9H-Purin-6-amine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-2-bromo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-60-9 CAPLUS

CN 2H-Purin-2-one, 6-amino-9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-61-0 CAPLUS

CN 9H-Purine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-6-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-62-1 CAPLUS

CN 9H-Purine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-63-2 CAPLUS

CN 9H-Purin-2-amine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-6-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-64-3 CAPLUS

CN 9H-Purine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-6-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-65-4 CAPLUS

CN 9H-Purine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-6-bromo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-67-6 CAPLUS

CN 9H-Purine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-6-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474323-69-8 CAPLUS


CN 9H-Purine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-2,6-dichloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474323-72-3 CAPLUS


CN 9H-Purine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]- (9CI) (CA INDEX NAME)



RN 474323-75-6 CAPLUS


CN 9H-Purin-2-amine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-

3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]- (9CI) (CA INDEX NAME)




RN 474323-77-8 CAPLUS

CN 2H-Purin-2-one, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474323-79-0 CAPLUS

CN 6H-Purin-6-one, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474323-81-4 CAPLUS

CN 6H-Purin-6-one, 2-amino-9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474323-83-6 CAPLUS

CN 1H-Purine-2,6-dione, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-3,9-dihydro- (9CI) (CA INDEX NAME)




RN 474323-85-8 CAPLUS

CN 9H-Purin-6-amine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]- (9CI) (CA INDEX NAME)




RN 474323-86-9 CAPLUS

CN 9H-Purine-2,6-diamine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]- (9CI) (CA INDEX NAME)




RN 474323-87-0 CAPLUS

CN 9H-Purin-6-amine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 474323-88-1 CAPLUS

CN 9H-Purin-6-amine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 474323-89-2 CAPLUS

CN 9H-Purin-6-amine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-2-bromo- (9CI) (CA INDEX NAME)




RN 474323-90-5 CAPLUS

CN 2H-Purin-2-one, 6-amino-9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474323-91-6 CAPLUS

CN 9H-Purine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 474323-92-7 CAPLUS

CN 9H-Purine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 474323-93-8 CAPLUS

CN 9H-Purin-2-amine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 474323-94-9 CAPLUS

CN 9H-Purine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-6-chloro- (9CI) (CA INDEX NAME)




RN 474323-95-0 CAPLUS

CN 9H-Purine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-6-bromo- (9CI) (CA INDEX NAME)




RN 474323-96-1 CAPLUS

CN 9H-Purine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-6-fluoro- (9CI) (CA INDEX NAME)




RN 474323-97-2 CAPLUS

CN 9H-Purine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-2,6-dichloro- (9CI) (CA INDEX NAME)




RN 474323-98-3 CAPLUS

CN 6H-Purine-6-thione, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474323-99-4 CAPLUS

CN 9H-Purin, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]- (9CI) (CA INDEX NAME)




RN 474324-01-1 CAPLUS

CN 9H-Purin-2-amine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]- (9CI) (CA INDEX NAME)




RN 474324-02-2 CAPLUS

CN 2H-Purin-2-one, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474324-03-3 CAPLUS

CN 6H-Purin-6-one, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474324-04-4 CAPLUS

CN 6H-Purin-6-one, 2-amino-9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474324-05-5 CAPLUS

CN 1H-Purine-2,6-dione, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-3,9-dihydro- (9CI) (CA INDEX NAME)




RN 474324-06-6 CAPLUS

CN 9H-Purin-6-amine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]- (9CI) (CA INDEX NAME)




RN 474324-08-8 CAPLUS

CN 9H-Purine-2,6-diamine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)]-.alpha.-L-lyxo-octofuranosyl]- (9CI) (CA INDEX NAME)




RN 474324-09-9 CAPLUS

CN 9H-Purin-6-amine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)]-.alpha.-L-lyxo-octofuranosyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 474324-10-2 CAPLUS

CN 9H-Purin-6-amine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)]-.alpha.-L-lyxo-octofuranosyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 474324-11-3 CAPLUS

CN 9H-Purin-6-amine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)]-.alpha.-L-lyxo-octofuranosyl]-2-bromo- (9CI) (CA INDEX NAME)




RN 474324-12-4 CAPLUS

CN 2H-Purin-2-one, 6-amino-9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)]-.alpha.-L-lyxo-octofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474324-13-5 CAPLUS

CN 9H-Purine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)]-.alpha.-L-lyxo-octofuranosyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 474324-14-6 CAPLUS

CN 9H-Purine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 474324-15-7 CAPLUS

CN 9H-Purin-2-amine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 474324-16-8 CAPLUS

CN 9H-Purine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-6-chloro- (9CI) (CA INDEX NAME)




RN 474324-17-9 CAPLUS

CN 9H-Purine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-6-bromo- (9CI) (CA INDEX NAME)




RN 474324-18-0 CAPLUS

CN 9H-Purine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-6-fluoro- (9CI) (CA INDEX NAME)




RN 474324-19-1 CAPLUS

CN 9H-Purine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-2,6-dichloro- (9CI) (CA INDEX NAME)




RN 474324-20-4 CAPLUS

CN 6H-Purine-6-thione, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474324-21-5 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2), P''-[[[(1R,8R,10R,11S)-11-hydroxy-10-(9H-purin-9-yl)-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474324-22-6 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2), P''-[[[(1R,8R,10R,11S)-10-(2-amino-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474324-23-7 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P''-[[[(1R,8R,10R,11S)-10-(1,2-dihydro-2-oxo-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474324-24-8 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P''-[[[(1R,8R,10R,11S)-10-(1,6-dihydro-6-oxo-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474324-25-9 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P''-[[[(1R,8R,10R,11S)-10-(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)



RN 474324-26-0 CAPLUS


CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P''-[[[(1R,8R,10R,11S)-11-hydroxy-10-(1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-9-yl)-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474324-27-1 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P''-[[[(1R,8R,10R,11S)-10-(6-amino-9H-purin-9-yl)-11-hydroxy-2,9-


dioxabicyclo[6.2.1]undec-8-yl)methyl] ester (9CI) (CA INDEX NAME)




RN 474324-28-2 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P''-[[[(1R,8R,10R,11S)-10-(2,6-diamino-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl)methyl] ester (9CI) (CA INDEX NAME)

RN 474324-29-3 CAPLUS


CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P''-[[[(1R,8R,10R,11S)-10-(6-amino-2-chloro-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl)methyl] ester (9CI) (CA INDEX NAME)

RN 474324-30-6 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P''-[[[(1R,8R,10R,11S)-10-(6-amino-2-fluoro-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl)methyl] ester (9CI) (CA INDEX NAME)


RN 474324-31-7 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P''-[[[(1R,8R,10R,11S)-10-(6-amino-2-bromo-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl)methyl] ester (9CI) (CA INDEX NAME)




RN 474324-32-8 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P'''-[[[(1R,8R,10R,11S)-10-(6-amino-1,2-dihydro-2-oxo-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474324-33-9 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P'''-[[[(1R,8R,10R,11S)-11-hydroxy-10-(6-methoxy-9H-purin-9-yl)-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474324-34-0 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P'''-[[[(1R,8R,10R,11S)-10-(2,6-dimethoxy-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474324-35-1 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P'''-[[[(1R,8R,10R,11S)-10-(2-amino-6-methoxy-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474324-36-2 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
 P''-[[[(1R,8R,10R,11S)-10-(6-chloro-9H-purin-9-yl)-11-hydroxy-2,9-
 dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474324-37-3 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
 P''-[[[(1R,8R,10R,11S)-10-(6-bromo-9H-purin-9-yl)-11-hydroxy-2,9-
 dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474324-38-4 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
 P''-[[[(1R,8R,10R,11S)-10-(6-fluoro-9H-purin-9-yl)-11-hydroxy-2,9-
 dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474324-39-5 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
 P''-[[[(1R,8R,10R,11S)-10-(2,6-dichloro-9H-purin-9-yl)-11-hydroxy-2,9-
 dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)



RN 474324-41-9 CAPLUS


CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
 P'''-[[[(1R,8R,10R,11S)-10-(1,6-dihydro-6-thioxo-9H-purin-9-yl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)



RN 474324-42-0 CAPLUS

CN 9H-Purine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-43-1 CAPLUS

CN 9H-Purine-2-amine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-44-2 CAPLUS

CN 2H-Purin-2-one, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-45-3 CAPLUS

CN 6H-Purin-6-one, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-46-4 CAPLUS

CN 6H-Purin-6-one, 2-amino-9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-47-5 CAPLUS

CN 1H-Purine-2,6-dione, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-3,9-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-48-6 CAPLUS

CN 9H-Purin-6-amine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-49-7 CAPLUS

CN 9H-Purine-2,6-diamine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-51-1 CAPLUS

CN 9H-Purin-6-amine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-2-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-52-2 CAPLUS

CN 9H-Purin-6-amine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-2-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-53-3 CAPLUS

CN 9H-Purin-6-amine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-2-bromo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-54-4 CAPLUS

CN 2H-Purin-2-one, 6-amino-9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-55-5 CAPLUS

CN 9H-Purine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-6-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-57-7 CAPLUS

CN 9H-Purine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-58-8 CAPLUS

CN 9H-Purin-2-amine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-6-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-59-9 CAPLUS

CN 9H-Purine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-6-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-60-2 CAPLUS

CN 9H-Purine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-6-bromo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-62-4 CAPLUS

CN 9H-Purine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-6-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-63-5 CAPLUS

CN 9H-Purine, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxohexofuranosyl]-2,6-dichloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474324-64-6 CAPLUS


CN 6H-Purine-6-thione, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxohexofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 474324-65-7 CAPLUS

CN 9H-Purine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyx-heptofuranosyl]- (9CI) (CA INDEX NAME)




RN 474324-66-8 CAPLUS

CN 9H-Purin-2-amine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyx-heptofuranosyl]- (9CI) (CA INDEX NAME)




RN 474324-67-9 CAPLUS

CN 2H-Purin-2-one, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyx-heptofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474324-68-0 CAPLUS

CN 6H-Purin-6-one, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474324-69-1 CAPLUS

CN 6H-Purin-6-one, 2-amino-9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474324-71-5 CAPLUS

CN 1H-Purine-2,6-dione, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-3,9-dihydro- (9CI) (CA INDEX NAME)




RN 474324-72-6 CAPLUS

CN 9H-Purin-6-amine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]- (9CI) (CA INDEX NAME)




RN 474324-73-7 CAPLUS

CN 9H-Purine-2,6-diamine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]- (9CI) (CA INDEX NAME)




RN 474324-74-8 CAPLUS

CN 9H-Purin-6-amine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 474324-75-9 CAPLUS

CN 9H-Purin-6-amine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 474324-76-0 CAPLUS

CN 9H-Purin-6-amine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-2-bromo- (9CI) (CA INDEX NAME)




RN 474324-78-2 CAPLUS

CN 2H-Purin-2-one, 6-amino-9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474324-79-3 CAPLUS

CN 9H-Purine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 474324-80-6 CAPLUS

CN 9H-Purine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 474324-81-7 CAPLUS

CN 9H-Purin-2-amine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 474324-82-8 CAPLUS

CN 9H-Purine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-6-chloro- (9CI) (CA INDEX NAME)




RN 474324-84-0 CAPLUS

CN 9H-Purine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-6-bromo- (9CI) (CA INDEX NAME)




RN 474324-85-1 CAPLUS

CN 9H-Purine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-6-fluoro- (9CI) (CA INDEX NAME)




RN 474324-86-2 CAPLUS

CN 9H-Purine, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-2,6-dichloro- (9CI) (CA INDEX NAME)




RN 474324-87-3 CAPLUS

CN 6H-Purine-6-thione, 9-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474324-88-4 CAPLUS

CN 9H-Purine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]- (9CI) (CA INDEX NAME)




RN 474324-89-5 CAPLUS

CN 9H-Purin-2-amine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]- (9CI) (CA INDEX NAME)




RN 474324-90-8 CAPLUS

CN 2H-Purin-2-one, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474324-91-9 CAPLUS

CN 6H-Purin-6-one, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474324-92-0 CAPLUS

CN 6H-Purin-6-one, 2-amino-9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474324-94-2 CAPLUS

CN 1H-Purine-2,6-dione, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-3,9-dihydro- (9CI) (CA INDEX NAME)




RN 474324-95-3 CAPLUS

CN 9H-Purin-6-amine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]- (9CI) (CA INDEX NAME)




RN 474324-96-4 CAPLUS

CN 9H-Purine-2,6-diamine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]- (9CI) (CA INDEX NAME)




RN 474324-97-5 CAPLUS

CN 9H-Purin-6-amine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 474324-98-6 CAPLUS

CN 9H-Purin-6-amine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 474325-00-3 CAPLUS

CN 9H-Purin-6-amine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-2-bromo- (9CI) (CA INDEX NAME)




RN 474325-01-4 CAPLUS

CN 2H-Purin-2-one, 6-amino-9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474325-02-5 CAPLUS

CN 9H-Purine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 474325-03-6 CAPLUS

CN 9H-Purine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)




RN 474325-04-7 CAPLUS

CN 9H-Purin-2-amine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-6-methoxy- (9CI) (CA INDEX NAME)




RN 474325-06-9 CAPLUS

CN 9H-Purine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-6-chloro- (9CI) (CA INDEX NAME)




RN 474325-07-0 CAPLUS

CN 9H-Purine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-6-bromo- (9CI) (CA INDEX NAME)




RN 474325-08-1 CAPLUS

CN 9H-Purine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-6-fluoro- (9CI) (CA INDEX NAME)




RN 474325-09-2 CAPLUS

CN 9H-Purine, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-2,6-dichloro- (9CI) (CA INDEX NAME)




RN 474325-10-5 CAPLUS

CN 6H-Purine-6-thione, 9-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)




RN 474325-11-6 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-10-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474325-12-7 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-10-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474325-13-8 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-10-(4-amino-2-oxo-1(2H)-pyrimidinyl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474325-15-0 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-10-(4-amino-5-methyl-2-oxo-1(2H)-pyrimidinyl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl)methyl] ester (9CI) (CA INDEX NAME)




RN 474325-16-1 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-10-(4-amino-5-fluoro-2-oxo-1(2H)-pyrimidinyl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl)methyl] ester (9CI) (CA INDEX NAME)




RN 474325-17-2 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-10-(4-chloro-2-oxo-1(2H)-pyrimidinyl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl)methyl] ester (9CI) (CA INDEX NAME)




RN 474325-18-3 CAPLUS

CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-11-hydroxy-10-(4-methoxy-2-oxo-1(2H)-pyrimidinyl)-2,9-dioxabicyclo[6.2.1]undec-8-yl)methyl] ester (9CI) (CA INDEX NAME)



RN 474325-19-4 CAPLUS


CN Triphosphoric acid, P-[[[(1R,8R,10R,11S)-10-(3,4-dihydro-2-oxo-4-thioxo-1(2H)-pyrimidinyl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)



RN 474325-21-8 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474325-22-9 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474325-23-0 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474325-24-1 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474325-25-2 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474325-27-4 CAPLUS

CN 2(1H)-Pyrimidinone, 1-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)]-.alpha.-L-lyxo-hexofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474325-28-5 CAPLUS

CN 2(1H)-Pyrimidinone, 1-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)]-.alpha.-L-lyxo-hexofuranosyl]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474325-29-6 CAPLUS


CN 2(1H)-Pyrimidinone, 1-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)]-.alpha.-L-lyxo-hexofuranosyl]-3,4-dihydro-4-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 474325-30-9 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]- (9CI) (CA INDEX NAME)




RN 474325-31-0 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 474325-32-1 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]- (9CI) (CA INDEX NAME)




RN 474325-34-3 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 474325-35-4 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)




RN 474325-36-5 CAPLUS


CN 2(1H)-Pyrimidinone, 1-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 474325-37-6 CAPLUS
 CN 2(1H)-Pyrimidinone, 1-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 474325-38-7 CAPLUS
 CN 2(1H)-Pyrimidinone, 1-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-3,4-dihydro-4-thioxo- (9CI) (CA INDEX NAME)



RN 474325-39-8 CAPLUS
 CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]- (9CI) (CA INDEX NAME)




RN 474325-40-1 CAPLUS
 CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 474325-41-2 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]- (9CI) (CA INDEX NAME)




RN 474325-42-3 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 474325-43-4 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)




RN 474325-44-5 CAPLUS

CN 2(1H)-Pyrimidinone, 1-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 474325-45-6 CAPLUS

CN 2(1H)-Pyrimidinone, 1-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 474325-46-7 CAPLUS

CN 2(1H)-Pyrimidinone, 1-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-3,4-dihydro-4-thio- (9CI) (CA INDEX NAME)




RN 474325-47-8 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P''-[[[(1R,8R,10R,11S)-10-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474325-48-9 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P''-[[[(1R,8R,10R,11S)-10-(3,4-dihydro-5-methyl-2,4-dioxo-1(2H)-pyrimidinyl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474325-49-0 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P''-[[[(1R,8R,10R,11S)-10-(4-amino-2-oxo-1(2H)-pyrimidinyl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474325-50-3 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P''-[[[(1R,8R,10R,11S)-10-(4-amino-5-methyl-2-oxo-1(2H)-pyrimidinyl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474325-51-4 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2), P''-[[[(1R,8R,10R,11S)-10-(4-amino-5-fluoro-2-oxo-1(2H)-pyrimidinyl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474325-52-5 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2), P''-[[[(1R,8R,10R,11S)-10-(4-chloro-2-oxo-1(2H)-pyrimidinyl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)




RN 474325-53-6 CAPLUS

CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2), P''-[[[(1R,8R,10R,11S)-11-hydroxy-10-(4-methoxy-2-oxo-1(2H)-pyrimidinyl)-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)



RN 474325-54-7 CAPLUS


CN Thiotriphosphoric acid ((HO)2P(O)OP(O)(OH)OP(S)(OH)2),
P''-[[[(1R,8R,10R,11S)-10-(3,4-dihydro-2-oxo-4-thioxo-1(2H)-pyrimidinyl)-11-hydroxy-2,9-dioxabicyclo[6.2.1]undec-8-yl]methyl] ester (9CI) (CA INDEX NAME)



RN 474325-55-8 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474325-56-9 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 474325-57-0 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-

tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-
 .alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474325-58-1 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474325-59-2 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 474325-60-5 CAPLUS

CN 2(1H)-Pyrimidinone, 1-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-

dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474325-61-6 CAPLUS

CN 2(1H)-Pyrimidinone, 1-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474325-62-7 CAPLUS

CN 2(1H)-Pyrimidinone, 1-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-3,4-dihydro-4-thioxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474325-63-8 CAPLUS


CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-

tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-
 .alpha.-L-lyxo-heptofuranosyl]- (9CI) (CA INDEX NAME)




RN 474325-64-9 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 474325-65-0 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]- (9CI) (CA INDEX NAME)




RN 474325-66-1 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 474325-67-2 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)]-.alpha.-L-lyxo-heptofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)




RN 474325-68-3 CAPLUS

CN 2(1H)-Pyrimidinone, 1-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)]-.alpha.-L-lyxo-heptofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 474325-69-4 CAPLUS

CN 2(1H)-Pyrimidinone, 1-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)]-.alpha.-L-lyxo-heptofuranosyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 474325-70-7 CAPLUS

CN 2(1H)-Pyrimidinone, 1-[2,7-anhydro-5,6-dideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-heptofuranosyl]-3,4-dihydro-4-thioxo- (9CI) (CA INDEX NAME)




RN 474325-71-8 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]- (9CI) (CA INDEX NAME)




RN 474325-72-9 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 474325-73-0 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]- (9CI) (CA INDEX NAME)




RN 474325-74-1 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 474325-75-2 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-5-fluoro- (9CI) (CA INDEX NAME)




RN 474325-76-3 CAPLUS

CN 2(1H)-Pyrimidinone, 1-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 474325-77-4 CAPLUS

CN 2(1H)-Pyrimidinone, 1-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 474325-78-5 CAPLUS


CN 2(1H)-Pyrimidinone, 1-[2,8-anhydro-5,6,7-trideoxy-4-C-(3,5,7,7-tetrahydroxy-5,7-dioxido-3-sulfido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-octofuranosyl]-3,4-dihydro-4-thioxo- (9CI) (CA INDEX NAME)



RN 474325-99-0 CAPLUS

CN 6H-Purine-6-thione, 9-[2,6-anhydro-5-deoxy-4-C-(3,5,7,7-tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-.alpha.-L-lyxo-hexofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 287737-32-0P 287737-33-1P 287737-34-2P
 287737-37-5P 287737-38-6P 287737-41-1P
 287737-42-2P 287737-43-3P 287737-46-6P
 287737-47-7P 287737-50-2P 287737-51-3P
 287737-54-6P 287737-55-7P 287737-56-8P
 287737-59-1P 474325-81-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(2'-O,4'-C-ethylene-bridged nucleoside triphosphates RNA polymerase substrates and influenza drug)

RN 287737-32-0 CAPLUS

CN Benzamide, N-[1-[2,6-anhydro-5-deoxy-4-C-[(phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-33-1 CAPLUS

CN Benzamide, N-[1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-34-2 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-37-5 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-[(phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-38-6 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-41-1 CAPLUS

CN Benzamide, N-[9-[2,6-anhydro-5-deoxy-4-C-[(phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]-9H-purin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-42-2 CAPLUS

CN Benzamide, N-[9-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-9H-purin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-43-3 CAPLUS

CN 9H-Purin-6-amine, 9-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-46-6 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-[(phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-47-7 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-50-2 CAPLUS

CN Benzamide, N-[1-[2,6-anhydro-5-deoxy-4-C-[(phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-5-methyl-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-51-3 CAPLUS

CN Benzamide, N-[1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-5-methyl-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-54-6 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-55-7 CAPLUS

CN Propanamide, N-[9-[2,6-anhydro-5-deoxy-4-C-[(phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]-6,9-dihydro-6-oxo-1H-purin-2-yl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-56-8 CAPLUS

CN Propanamide, N-[9-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-6,9-dihydro-6-oxo-1H-purin-2-yl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-59-1 CAPLUS

CN 6H-Purin-6-one, 2-amino-9-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474325-81-0 CAPLUS


CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-[(phosphonoxy)methyl]-.alpha.-L-lyxo-hexofuranosyl]-, compd. with N,N-diethylethanamine (9CI) (CA INDEX NAME)

CM 1

CRN 474325-80-9

CMF C11 H15 N2 O9 P


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



L15 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:648429 CAPLUS

DOCUMENT NUMBER: 137:217175

TITLE: Preparation of 2'-O,4'-C-ethylene nucleoside analogs
and oligonucleotide analogs and nucleic acid reagent
and drugs containing them

INVENTOR(S): Kaneko, Masakatsu; Morita, Hiroshi; Imanishi, Takeshi

PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 49 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002241393	A2	20020828	JP 2001-241033	20010808
PRIORITY APPLN. INFO.:			JP 2000-242247	A 20000810
OTHER SOURCE(S):		MARPAT 137:217175		

GI



AB Nucleic acid reagents contg. new oligonucleotide analogs or drugs contg. them, which exhibit stability in vivo, excellent antisense and antigene activity, or excellent activity as probes for detecting specific genes or primers for initiating amplification of specific genes (no data), drugs contg. them, and intermediates thereof are prepd. Nucleic acid reagents contg. compds. represented by general formula [I; R1, R2 = H, HO-protecting group for nucleic acid synthesis, P(O)(OH)₂ optionally protected by a protecting group for nucleic acid synthesis, PR₃R₄ (wherein R₃, R₄ = HO, SH, or NH₂ optionally protected by a protecting group for nucleic acid synthesis, C1-4 alkoxy, C1-4 alkylthio, C1-5 cyanoalkoxy, mono or di(C1-4 alkyl)amino); A = C1-4 alkylene; B = purin-9-yl or 2-oxo-1,2-dihydropyrimidin-1-yl optionally substituted by HO, SH, or NH₂ optionally protected by a protecting group for nucleic acid synthesis, mono or di(C1-4 alkyl)amino, C1-4 alkyl, or halo] or salts thereof are claimed. Oligonucleotides contg. a structure represented by formula (II; A, B = same as above) are also claimed. Thus, 500 mg trimethylsilylated thymine was added to a soln. of 650 mg 1,2-di-O-acetyl-3,5-di-O-benzyl-4-[2-(p-toluenesulfonyloxy)ethyl]-.alpha.-D-erythropentofuranose in 15 mL 1,2-dichloroethane, followed by adding 0.36 mL trimethylsilyl triflate, and the resulting mixt. was stirred at room temp. 50.degree. for 1 h to give 60% 2'-O-acetyl-3',5'-di-O-benzyl-4-[2-(p-toluenesulfonyloxy)ethyl]uridine which (418 mg) was dissolved in a 65:30:5 mixt. of pyridine, MeOH, and H₂O (5 mL), treated with 2 N aq. NaOH at 0.degree., and stirred at room temp. for 15 min to give 79% 3',5'-di-O-benzyl-2'-O,4'-C-ethylene-5-methyluridine (III). III (1.45 g) was dried by azeotropic evapn. with anhyd. pyridine, dissolved in anhyd. pyridine, treated with 2.59 g 4,4'-dimethoxytrityl chloride, and stirred overnight at room temp. to give 81% 5'-O-(4,4'-dimethoxytrityl)-2'-O,4'-C-ethylene-5-methyluridine which (4.72 g) was similarly dried by anhyd. pyridine, dissolved in 142 mL anhyd. CH₂Cl₂, treated dropwise with 2.16 mL 2-cyanoethyl N,N-diisopropylchlorophosphoramidite, and stirred at room temp. for 6 h to give 5'-O-(4,4'-dimethoxytrityl)-2'-O,4'-C-ethylene-5-methyluridine-3'-O-(2-cyanoethyl N,N-diisopropylphosphoramidite) (IV). An oligonucleotide analog, 5'-gcgttlttlttlttgct-3' (V; tl = 2'-O,4'-C-ethylenethymidine), was prepd. by a PerkinElmer ABI model 392 DNA/RNA synthesizer using IV. V and 5'-agcaaaaaacgc-3' showed T_m of 75.degree. vs. 44.degree. for natural 5'-gcgttttttgct-3'.

IT 287737-32-0P 287737-33-1P 287737-35-3P
 287737-37-5P 287737-38-6P 287737-39-7P
 287737-40-0P 287737-41-1P 287737-42-2P
 287737-44-4P 287737-46-6P 287737-47-7P
 287737-48-8P 287737-50-2P 287737-51-3P
 287737-52-4P 287737-55-7P 287737-56-8P
 287737-57-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. of 2'-O,4'-C-ethylene nucleoside analogs and oligonucleotide analogs and nucleic acid reagent and drugs contg. them)

RN 287737-32-0 CAPLUS

CN Benzamide, N-[1-[2,6-anhydro-5-deoxy-4-C-[(phenylmethoxy)methyl]-3-O-

(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-33-1 CAPLUS

CN Benzamide, N-[1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-35-3 CAPLUS

CN Benzamide, N-[1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-37-5 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-
[(phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]-5-
methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-38-6 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-
.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-39-7 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-4-C-[[bis(4-
methoxyphenyl)phenylmethoxy]methyl]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-
5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-40-0 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy)methyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-41-1 CAPLUS

CN Benzamide, N-[9-[2,6-anhydro-5-deoxy-4-C-[(phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]-9H-purin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-42-2 CAPLUS

CN Benzamide, N-[9-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-9H-purin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-44-4 CAPLUS

CN Benzamide, N-[9-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-9H-purin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-46-6 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-
[(phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-47-7 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-
.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287737-48-8 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-4-C-[[bis(4-

methoxyphenyl]phenylmethoxy)methyl]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-50-2 CAPLUS

CN Benzamide, N-[1-[2,6-anhydro-5-deoxy-4-C-[(phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-5-methyl-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-51-3 CAPLUS

CN Benzamide, N-[1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-5-methyl-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-52-4 CAPLUS

CN Benzamide, N-[1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-5-methyl-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-55-7 CAPLUS


CN Propanamide, N-[9-[2,6-anhydro-5-deoxy-4-C-[(phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]-6,9-dihydro-6-oxo-1H-purin-2-yl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287737-56-8 CAPLUS
 CN Propanamide, N-[9-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-6,9-dihydro-6-oxo-1H-purin-2-yl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287737-57-9 CAPLUS
 CN Propanamide, N-[9-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-6,9-dihydro-6-oxo-1H-purin-2-yl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 287737-34-2P 287737-36-4P 287737-43-3P
 287737-45-5P 287737-49-9P 287737-53-5P
 287737-54-6P 287737-58-0P 287737-59-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of 2'-O,4'-C-ethylene nucleoside analogs and oligonucleotide analogs and nucleic acid reagent and drugs contg. them)
 RN 287737-34-2 CAPLUS
 CN 2(1H)-Pyrimidinone, 4-amino-1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287737-36-4 CAPLUS
 CN Benzamide, N-[1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methoxy]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287737-43-3 CAPLUS
 CN 9H-Purin-6-amine, 9-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-45-5 CAPLUS
 CN Benzamide, N-[9-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methoxy]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

L-lyxo-hexofuranosyl]-9H-purin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-49-9 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-53-5 CAPLUS

CN Benzamide, N-[1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-5-methyl-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-54-6 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-
.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-58-0 CAPLUS

CN Propanamide, N-[9-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]met
hyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-
.alpha.-L-lyxo-hexofuranosyl]-6,9-dihydro-6-oxo-1H-purin-2-yl]-2-methyl-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-59-1 CAPLUS

CN 6H-Purin-6-one, 2-amino-9-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:900078 CAPLUS

DOCUMENT NUMBER: 136:263373

TITLE: 2'-O,4'-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug

AUTHOR(S): Morita, Koji; Hasegawa, Chikako; Kaneko, Masakatsu; Tsutsumi, Shinya; Sone, Junko; Ishikawa, Tomio; Imanishi, Takeshi; Koizumi, Makoto

CORPORATE SOURCE: Sankyo Co., Ltd., Exploratory Chemistry Research Laboratories, Tokyo; 140-8710, Japan

SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), Volume Date 2002, 12(1), 73-76
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To develop antisense oligonucleotides, novel nucleosides, 2'-O,4'-C-ethylene nucleosides and their corresponding phosphoramidites,

were synthesized as building blocks. The ^1H NMR anal. showed that the 2'-O,4'-C-ethylene linkage of these nucleosides restricts the sugar puckering to the N-conformation as well as the linkage of 2'-O,4'-C-methylene nucleosides which are known as bridged nucleic acids (BNA) or locked nucleic acids (LNA). The ethylene-bridged nucleic acids (ENA) showed a high binding affinity for the complementary RNA strand ($\Delta T_m = +5.2$.degree.C/modification) and were more nuclease-resistant than natural DNA and BNA/LNA. These results indicate that ENA have better properties as antisense oligonucleotides than BNA/LNA.

IT 403822-02-6P


RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of 2'-O,4'-C-ethylene-bridged nucleic acids which are nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug use)

RN 403822-02-6 CAPLUS

CN Thymidine, thymidylyl-(3'.fwdarw.5')-2'-O,4'-C-1,2-ethanediyl-5-methyluridylyl-(3'.fwdarw.5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 287737-37-5P 287737-38-6P 287737-39-7P

287737-40-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of 2'-O,4'-C-ethylene-bridged nucleic acids which are nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug use)

RN 287737-37-5 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-[(phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-38-6 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-39-7 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-40-0 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:573812 CAPLUS

DOCUMENT NUMBER: 133:164266

TITLE: Preparation of novel nucleosides and oligonucleotide analogues having antisense or antigene activity

INVENTOR(S): Kaneko, Masakatsu; Morita, Koji; Imanishi, Takeshi

PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan

SOURCE: PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047599	A1	20000817	WO 2000-JP725	20000210
W: AU, BR, CA, CN, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, TR, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1152009	A1	20011107	EP 2000-902887	20000210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 2000008131	A	20020409	BR 2000-8131	20000210
JP 2000297097	A2	20001024	JP 2000-34560	20000214
US 2002147332	A1	20021010	US 2001-925673	20010809
NO 2001003899	A	20011010	NO 2001-3899	20010810
PRIORITY APPLN. INFO.:			JP 1999-33863	A 19990212
			WO 2000-JP725	W 20000210
OTHER SOURCE(S):		MARPAT 133:164266		

GI



AB Comps. represented by general formula [I; wherein R1 and R2 are each independently hydrogen, a hydroxyl-protecting group, a phosphoric acid group, or -P(R3)R4 (wherein R3 and R4 are each independently C1-5 cyanoalkoxy, amino substituted with C1-4 alkyl, or the like); A is C1-4 alkylene; and B is optionally substituted purin-9-yl or 2-oxypyrimidin-1-yl] and salts thereof and novel oligonucleotide analogs prepd. by using the same as the intermediates, which exhibit stable and excellent antisense activities and are useful as probes for detecting specific genes or as primers for initiating gene amplification, are prepd. Thus, alkylation of 2'-O,4'-C-ethylene-5-methyluridine by 4,4'-dimethoxytrityl chloride in pyridine at room temp. overnight followed by condensation with 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite in the presence of diisopropylethylamine in CH₂Cl₂ gave phosphoramidite (II). Oligonucleotide analog 5'-d(gcgxxxxxxgct)-3' (III; x = 2'-O,4'-C-ethylene-5-methyluridine residue) was prepd. by ABI model 392 DNA/RNA synthesizer and the phosphoramidite solid-phase method using II. DNA-DNA duplex, III.5'-d(agcaaaaaacgc)-3', and DNA-RNA duplex III.5'-r(agcaaaaaacgc)-3' showed T_m of 61 and 75.degree., resp., as compared to 48 and 44.degree. for 5'-d(gcgttttttgct)(natural sequence).3'-5'-d(agcaaaaaacgc)-3' and 5'-d(gcgttttttgct).3'-5'-r(agcaaaaaacgc)-3', resp.

IT 287737-32-OP 287737-33-1P 287737-35-3P
 287737-36-4P 287737-37-5P 287737-38-6P
 287737-39-7P 287737-40-OP 287737-41-1P
 287737-42-2P 287737-44-4P 287737-45-5P
 287737-46-6P 287737-48-8P 287737-49-9P
 287737-50-2P 287737-51-3P 287737-52-4P
 287737-53-5P 287737-55-7P 287737-57-9P
 287737-58-OP


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of novel nucleosides and oligonucleotide analogs as antisense or antigene oligonucleotides or primers for gene amplifications)

RN 287737-32-0 CAPLUS

CN Benzamide, N-[1-[2,6-anhydro-5-deoxy-4-C-[(phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-33-1 CAPLUS

CN Benzamide, N-[1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-35-3 CAPLUS

CN Benzamide, N-[1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287737-36-4 CAPLUS

CN Benzamide, N-[1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 287737-37-5 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-
 [(phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]-5-
 methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-38-6 CAPLUS


CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-
 .alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287737-39-7 CAPLUS
 CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287737-40-0 CAPLUS
 CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287737-41-1 CAPLUS
 CN Benzamide, N-[9-[2,6-anhydro-5-deoxy-4-C-[(phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]-9H-purin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-42-2 CAPLUS

CN Benzamide, N-[9-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-9H-purin-6-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-44-4 CAPLUS


CN Benzamide, N-[9-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-9H-purin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287737-45-5 CAPLUS
 CN Benzamide, N-[9-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-9H-purin-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287737-46-6 CAPLUS
 CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-[[phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-48-8 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-49-9 CAPLUS


CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287737-50-2 CAPLUS
 CN Benzamide, N-[1-[2,6-anhydro-5-deoxy-4-C-[(phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-5-methyl-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287737-51-3 CAPLUS
 CN Benzamide, N-[1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-5-methyl-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287737-52-4 CAPLUS
 CN Benzamide, N-[1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-5-methyl-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-53-5 CAPLUS

CN Benzamide, N-[1-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-.alpha.-L-lyxo-hexofuranosyl]-1,2-dihydro-5-methyl-2-oxo-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 287737-55-7 CAPLUS


CN Propanamide, N-[9-[2,6-anhydro-5-deoxy-4-C-[(phenylmethoxy)methyl]-3-O-(phenylmethyl)-.alpha.-L-lyxo-hexofuranosyl]-6,9-dihydro-6-oxo-1H-purin-2-yl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287737-57-9 CAPLUS
 CN Propanamide, N-[9-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-5-deoxy-α-L-lyxo-hexofuranosyl]-6,9-dihydro-6-oxo-1H-purin-2-yl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287737-58-0 CAPLUS
 CN Propanamide, N-[9-[2,6-anhydro-4-C-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-5-deoxy-α-L-lyxo-hexofuranosyl]-6,9-dihydro-6-oxo-1H-purin-2-yl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 287737-34-2P 287737-43-3P 287737-47-7P
287737-54-6P 287737-56-8P 287737-59-1P


RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of novel nucleosides and oligonucleotide analogs as antisense
or antigene oligonucleotides or primers for gene amplifications)

RN 287737-34-2 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-
.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-43-3 CAPLUS

CN 9H-Purin-6-amine, 9-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-
lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-47-7 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-54-6 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-56-8 CAPLUS

CN Propanamide, N-[9-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-6,9-dihydro-6-oxo-1H-purin-2-yl]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287737-59-1 CAPLUS

CN 6H-Purin-6-one, 2-amino-9-[2,6-anhydro-5-deoxy-4-C-(hydroxymethyl)-.alpha.-L-lyxo-hexofuranosyl]-1,9-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT